Professional Documents
Culture Documents
M. Hafiizh Alfarrisi, 0606065831
Medical care
Global Strategy for Asthma Management and
Prevention" include:
± Achieve and maintain control of asthma symptoms
± Maintain normal activity levels, including exercise
± Maintain pulmonary function as close to normal as
possible
± Prevent asthma exacerbations
± Avoid adverse effects from asthma medications
± Prevent asthma mortality
_he long-term outpatient
management of asthma
Objective measures of lung function
Environmental control measures and
avoidance of risk factors
Comprehensive pharmacologic therapy
Patient education
asthma treatment strategies
_he functions of asthma assessment and
monitoring are closely linked to the concepts of
severity, control, and responsiveness to
treatment.
Asthma severity is measured most easily and
directly in a patient
Asthma control is the degree to which the
manifestations of asthma are minimized and the
goals of therapy
Asthma responsiveness is the ease with which
asthma control is achieved by therapy.
Èiet
from prospective cohort studies,
association between asthma and obesity
relationship between body mass index and
the risk of developing asthma.
Activity
Activity is generally limited by patients' ability to
exercise and their response to medications.
No specific limitations are recommended for
patients with asthma, although they should avoid
exposure to agents that may exacerbate their
disease.
A significant number of patients with asthma
also have exercise-induced bronchospasm
Asthma medications are generally divided
into 2 categories:
± quick relief (also called reliever medications)
± long-term control (also called controller
medications)
Ëuick relief medications
are used to relieve acute asthma
exacerbations and to prevent exercise-
induced asthma (EIA), or exercise-induced
bronchospasm (EIB) symptoms.
_hese medications include:
± short-acting beta-agonists (SABAs),
± anticholinergics,
± and systemic corticosteroids.
ong-term control medications
inhaled corticosteroids (ICSs),
cromolyn sodium,
nedocromil,
long-acting beta-agonists (ABAs),
combination inhaled corticosteroids and
long-acting beta-agonists,
Methylxanthines
leukotriene antagonists
_he newest asthma medication
omalizumab (Xolair)
± a recombinant ÈNA-derived humanized Ig G
monoclonal antibody that binds selectively to
human Ig E on the surface of mast cells and
basophils.
± _he drug reduces mediator release, which
promotes an allergic response.
± It is indicated for moderate-to-severe
persistent asthma, in whom symptoms are not
controlled by inhaled corticosteroids.
Ò
_hese agents relieve reversible
bronchospasm by relaxing the smooth
muscles of the bronchi.
± evalbuterol
± Salmeterol
± Albuterol
'
_hese are highly potent agents that are
the primary ÈOC for treatment of chronic
asthma and prevention of acute asthma
exacerbations.
± _riamcinolone
± Beclomethasone
± Prednisone
Ò
Bronchodilators provide symptomatic relief
of bronchospasm due to acute asthma
exacerbation (short-acting agents) or long-
term control of symptoms (long-acting
agents). Also used as the primary
medication for prophylaxis of exercise-
induced asthma.
± Ipratropium
± _heophylline
Mast cell stabilizers prevent the release of
mediators from mast cells that cause
airway inflammation and bronchospasm.
_hey are indicated for maintenance
therapy of mild-to-moderate asthma or
prophylaxis for exercise-induced
bronchospasm.
± Cromolyn
_hese recombinant ÈNA-derived
humanized immunoglobulin G monoclonal
antibodies bind selectively to human
immunoglobulin E on the surface of mast
cells and basophils. _hey reduce mediator
release, which promotes an allergic
response. _hey are indicated for
moderate-to-severe persistent asthma
± Omalizumab
_hese drugs are direct antagonists of
mediators responsible for airway
inflammation in asthma. _hey are used for
prophylaxis of exercise-induced
bronchospasm and long-term treatment of
asthma as alternative to low doses of
inhaled corticosteroids.
± Montelukast
Exposure to irritants or allergens has been
shown to increase asthma symptoms and
cause exacerbations.
evaluate patients with persistent asthma
for allergen exposures and sensitivity to
seasonal allergens.
Skin testing
avoid exposure to:
Environmental tobacco smoke
Exertion during high levels of air pollution
Use of beta-blockers
Avoidance of aspirin and other nonsteroidal anti-
inflammatory drugs if the patient is sensitive
Avoidance of sulfites or other food
items/additives to which the patient may be
sensitive
Occupational exposures
'
_he most common complications of
asthma include:
± pneumonia,
± pneumothorax or pneumomediastinum,
± and respiratory failure requiring intubation in
severe exacerbations.
ýisk factors for death from asthma:
Previous severe asthma exacerbation (eg, intubation or
ICU admission for asthma)
_wo or more hospitalizations for asthma in the past year
_hree or more emergency department visits for asthma
in the past year
Hospitalization or emergency department visit for asthma
in the past month
Using more than 2 canisters of short-acting beta-
agonists per month
Èifficulty perceiving asthma symptoms or severity of
exacerbations
ï Comorbidities - Cardiovascular disease, other chronic
lung disease, chronic psychiatric disease
Approximately half the children diagnosed with
asthma in childhood outgrow their disease by
late adolescence or early adulthood and require
no further treatment.
Patients with poorly controlled asthma develop
long-term changes over time (ie, with airway
remodeling). _his can lead to chronic symptoms
and a significant irreversible component to their
disease.
Many patients who develop asthma at an older
age also tend to have chronic symptoms.
Integrate patient education into every aspect of
asthma care.
All members of the health care team, including
nurses, pharmacists, and respiratory therapists,
provide education.
Clinicians teach patients asthma self-
management based on basic asthma facts, self-
monitoring techniques, the role of medications,
inhaler use, and environmental control
measures.
Èevelop treatment goals for the patient
and family.
Èevelop a written, individualized, daily
self-management plan.
Several well-validated asthma action plans
are now available and are key in the
management of asthma.
_hank you
http://emedicine.medscape.com/article/29
6301-followup